aTYR PHARMA INC (ATYR)

0.19 0.01 (5.89%)

As of 2026-10-15 14:21:25 EST

aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.

Traded asNasdaq: ATYR
ISINUS0021202025
CIK0001339970
LEI529900ENQUXMC5EBKO36
EIN203435077
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOSanjay S Shukla
Employees55
Fiscal Year End1231
Address10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
Phone8587318389
Websitehttp://atyrpharma.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
ATYRaTYR PHARMA INC2026-10-15 14:21:250.190.015.89
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
ATYR0001339970aTYR PHARMA INCUS0021202025529900ENQUXMC5EBKO36203435077Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE10240 SORRENTO VALLEY ROADSAN DIEGOCA92121UNITED STATESUS858731838910240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 9212110240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121—Biotechnology2005Sanjay S Shukla55http://atyrpharma.com463,822,83498,087,42598,087,425aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.2026-10-09 05:23:03
This is a preview of the latest data. Subscribe to access the full data.
ATYR Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
ATYR Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2025463,822,834347,580,105299.012398,051,2129,192,60010.3452
2024116,242,729-4,531,687-3.752288,858,61221,108,58831.1566
2023120,774,41643,580,30956.455567,750,02414,587,97227.4406
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Nancy E. DenyesGeneral Counsel2025451,570——108,37711,2141,284,841
Jill M. BroadfootChief Financial Officer2025471,790——113,22911,2141,309,913
Sanjay S. ShuklaCEO, President2025638,977——210,86211,2143,456,253
Sanjay S. ShuklaCEO, President2024580,887——246,87710,9981,480,522
Nancy E. DenyesGeneral Counsel2024410,517——139,57618,772729,305
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202558
202459
202359
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue190,000235,000353,000
Cost Of Revenue———
Gross Profit190,000235,000353,000
Research And Development Expenses60,219,00054,372,00042,293,000
General And Administrative Expenses17,598,00013,777,00012,979,000
Operating Expenses77,817,00068,149,00055,272,000
Operating Income-77,627,000-67,914,000-54,919,000
Net Income-74,118,000-64,023,000-50,389,000
Earnings Per Share Basic-0.8-0.86-0.94
Earnings Per Share Diluted-0.8-0.86-0.94
Weighted Average Shares Outstanding Basic92,985,35974,261,26553,606,488
Weighted Average Shares Outstanding Diluted92,985,35974,261,26553,606,488
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents10,743,00011,055,00022,544,000
Marketable Securities Current67,944,00061,070,00075,622,000
Accounts Receivable———
Inventories———
Non Trade Receivables873,0001,736,0002,436,000
Other Assets Current677,0008,093,0002,390,000
Total Assets Current80,237,00081,954,000102,992,000
Marketable Securities Non Current———
Property Plant And Equipment4,263,0004,850,0005,531,000
Other Assets Non Current148,00066,000131,000
Total Assets Non Current12,766,00014,876,00017,661,000
Total Assets93,003,00096,830,000120,653,000
Accounts Payable3,891,0004,323,0003,529,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current9,791,0009,392,00011,559,000
Total Liabilities Current15,148,00014,967,00016,416,000
Long Term Debt———
Other Liabilities Non Current———
Total Liabilities Non Current10,375,00011,844,00013,579,000
Total Liabilities25,523,00026,811,00029,995,000
Common Stock98,00084,00063,000
Retained Earnings-606,164,000-532,046,000-468,023,000
Accumulated Other Comprehensive Income-8,000-40,000-74,000
Total Shareholders Equity67,480,00070,019,00090,658,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization664,000708,000592,000
Share Based Compensation Expense———
Other Non Cash Income Expense12,0003,0006,000
Change In Accounts Receivable———
Change In Inventories———
Change In Non Trade Receivables-863,000-402,000-9,054,000
Change In Other Assets-7,334,0005,638,000-622,000
Change In Accounts Payable-33,000-1,339,0003,262,000
Change In Other Liabilities———
Cash From Operating Activities-61,986,000-69,119,000-33,221,000
Purchases Of Marketable Securities93,445,00069,103,000106,977,000
Sales Of Marketable Securities88,457,00086,394,00091,050,000
Acquisition Of Property Plant And Equipment77,00065,0004,215,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-5,053,00017,233,000-20,127,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock19,00000
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities66,011,00039,864,00066,230,000
Change In Cash-1,028,000-12,022,00012,882,000
Cash At End Of Period10,743,00011,055,00022,544,000
Income Taxes Paid———
Interest Paid94,000137,000172,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-0.8-0.86-0.94
Price To Earnings Ratio-0.9789-4.2093-1.5
Earnings Growth Rate-6.9767-8.5106-41.25
Price Earnings To Growth Ratio0.14030.49460.0364
Book Value Per Share0.72570.94291.6912
Price To Book Ratio1.07913.83930.8337
Ebitda-73,454,000-63,315,000-49,797,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures77,00027,0003,064,000
Free Cash Flow-62,063,000-69,146,000-36,285,000
Return On Equity-1.0984-0.9144-0.5558
One Year Beta0.99360.72670.7842
Three Year Beta0.87160.82220.8375
Five Year Beta0.86210.80220.8372
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Yaras BrandonChief Financial Officer2026-10-01410,000A410,000
SCHIMMEL PAULDirector2026-05-27100,000A779,143
SCHIMMEL PAULDirector2026-05-1150,000A50,000
Zaknoen SaraDirector2026-05-1150,000A50,000
Lucas SvetlanaDirector2026-05-1150,000A50,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
NFSG Corp2026-09-306001,9790.3032
Essential Partners LLC2026-09-30732420.3017
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC2026-09-305,38521,0920.2553
True Wealth Design, LLC2026-09-30923010.3056
Farther Finance Advisors, LLC2026-09-30351150.3043
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Advisors' Inner Circle Fund III2026-07-31I SharesKCXIX537260.820.0001
RUSSELL INVESTMENT CO2026-07-31Class MRUNTX-16,752-8,136.45-0.0008
RUSSELL INVESTMENT CO2026-07-31Class R6RSCRX-16,752-8,136.45-0.0008
RUSSELL INVESTMENT CO2026-07-31Class SRLESX-16,752-8,136.45-0.0008
RUSSELL INVESTMENT CO2026-07-31Class CRLECX-16,752-8,136.45-0.0008
This is a preview of the latest data. Subscribe to access the full data.